-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Dresbuxelimab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Dresbuxelimab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: CBP-1008 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seclidemstat Mesylate in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seclidemstat Mesylate in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seclidemstat Mesylate in Ewing Sarcoma Drug Details: Seclidemstat (SP-2577) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Triplex in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Triplex in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Triplex in Multiple Myeloma (Kahler Disease) Drug Details: Triplex is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Solid Tumor Drug Details: Relatlimab (BMS-986016) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ligufalimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ligufalimab in Non-Small Cell Lung Cancer Drug Details: Ligufalimab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Penpulimab in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Penpulimab in Glioblastoma Multiforme (GBM) Drug Details: Penpulimab is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Penpulimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Penpulimab in Non-Small Cell Lung Cancer Drug Details: Penpulimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Pancreatic Cancer Drug Details: Ivonescimab (AK-112) is under development...